Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single institution retrospective study of sargramostim (glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) in patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively

Trial Profile

A single institution retrospective study of sargramostim (glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) in patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Mycoses
  • Focus Therapeutic Use

Most Recent Events

  • 22 Dec 2022 New trial record
  • 15 Dec 2022 According to a Partner Therapeutics media release, this research was led by Thomas J. Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM, of the Transplantation-Oncology Infectious Disease Program at Weill Cornell Medicine and Center for Innovative Therapeutics and Diagnostics, and Tempe K. Chen, MD, of MemorialCare Miller Children's & Women's Hospital Long Beach and Division of Infectious Diseases at University of California Irvine School of Medicine.
  • 15 Dec 2022 Results (N=15) published in a Partner Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top